Company profile: Crescent Biopharma
1.1 - Company Overview
Company description
- Provider of novel precision-engineered biologics targeting verified biology to treat solid tumors, originating from discoveries at Paragon Therapeutics.
Products and services
- Targeted Medicines for Solid Tumors: Crescent Biopharma architects novel, oncology-focused medicines targeting verified biology to improve care for patients with solid tumors
- Paragon-Sourced Biologic Programs: Crescent Biopharma produces discovery-derived biologics for solid tumors that originate from Paragon Therapeutics discoveries, targeting verified biology
- Novel Precision-Engineered Biologics: Crescent Biopharma develops biologics aimed at treating solid tumors by targeting verified biology and originating from Paragon Therapeutics discoveries
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Crescent Biopharma
Immedica
HQ: Sweden
Website
- Description: Provider of niche/specialty care pharmaceutical products with commercial coverage across Europe and the Middle East. Portfolio includes Akynzeo for prevention of chemotherapy-induced nausea and vomiting; Ammonaps for urea cycle disorders; Arlevert for vertigo and tinnitus; Loargys for Arginase 1 Deficiency; Neofordex high-dose dexamethasone; and Nor-NOHA Blood Collection Tubes for blood collection and diagnostic purposes.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Immedica company profile →
Marengo Therapeutics
HQ: United States
Website
- Description: Provider of T cell–modulating antibody platforms and therapeutics, including the STAR bi-functional molecule platform pairing anti-Vβ antibodies with costimulatory signals for antigen-rich 'hot' tumors; the TriSTAR T cell engager for antigen-low 'cold' tumors; TCR-targeting antibodies; an antibody technology platform using genomics and TCR sequencing; and STAR0602, in Phase I/II (START-001) for advanced antigen-rich solid tumors.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Marengo Therapeutics company profile →
Advesya
HQ: France
Website
- Description: Provider of therapies for difficult-to-treat cancers, focusing on immuno-oncology and hematological malignancies, leveraging biochemistry and molecular and cellular biology expertise. Offers ADV-101, a topoisomerase I inhibitor antibody-drug conjugate targeting IL-1RAP for esophageal cancer, delivering cytotoxic agents directly to cancer cells.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Advesya company profile →
Circio
HQ: Norway
Website
- Description: Provider of active immunotherapy cancer vaccines for post-operation treatments, including TG01, a peptide-based vaccine targeting KRAS/RAS driver mutations in clinical trials for RAS-mutated pancreatic cancer, lung cancer, and multiple myeloma, and circVec, a genetic medicine platform producing multifunctional circular RNA from DNA and viral vectors with enhanced, durable protein expression versus classic mRNA systems.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Circio company profile →
Carrick Therapeutics
HQ: Ireland
Website
- Description: Provider of cancer therapeutics targeting molecular pathways driving aggressive and resistant cancers. Pipeline includes Samuraciclib (CT7001), an oral CDK7 inhibitor in clinical development for HR+, HER2- advanced breast cancer and triple negative breast cancer, and a CDK12/13 inhibitor/Cyclin-K glue-degrader in IND enabling toxicology studies targeting genomic stability and DNA repair.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Carrick Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Crescent Biopharma
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Crescent Biopharma
2.2 - Growth funds investing in similar companies to Crescent Biopharma
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Crescent Biopharma
4.2 - Public trading comparable groups for Crescent Biopharma
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →